A learning health system approach to the COVID-19 pandemic: System-wide changes in clinical practice and 30-day mortality among hospitalized patients.
dexamethasone
regulatory guidelines
remdesivir
scientific dissemination
temporal trends
tocilizumab
Journal
Learning health systems
ISSN: 2379-6146
Titre abrégé: Learn Health Syst
Pays: United States
ID NLM: 101708071
Informations de publication
Date de publication:
Jul 2022
Jul 2022
Historique:
received:
25
08
2021
revised:
05
01
2022
accepted:
06
01
2022
entrez:
21
7
2022
pubmed:
22
7
2022
medline:
22
7
2022
Statut:
epublish
Résumé
Rapid, continuous implementation of credible scientific findings and regulatory approvals is often slow in large, diverse health systems. The coronavirus disease 2019 (COVID-19) pandemic created a new threat to this common "slow to learn and adapt" model in healthcare. We describe how the University of Pittsburgh Medical Center (UPMC) committed to a rapid learning health system (LHS) model to respond to the COVID-19 pandemic. A treatment cohort study was conducted among 11 429 hospitalized patients (pediatric/adult) from 22 hospitals (PA, NY) with a primary diagnosis of COVID-19 infection (March 19, 2020 - June 6, 2021). Sociodemographic and clinical data were captured from UPMC electronic medical record (EMR) systems. Patients were grouped into four time-defined patient "waves" based on nadir of daily hospital admissions, with wave 3 (September 20, 2020 - March 10, 2021) split at its zenith due to high volume with steep acceleration and deceleration. Outcomes included changes in clinical practice (eg, use of corticosteroids, antivirals, and other therapies) in relation to timing of internal system analyses, scientific publications, and regulatory approvals, along with 30-day rate of mortality over time. The mean (SD) daily number of admissions across hospitals was 26 (29) with a maximum 7-day moving average of 107 patients. System-wide implementation of the use of dexamethasone, remdesivir, and tocilizumab occurred within days of release of corresponding seminal publications and regulatory actions. After adjustment for differences in patient clinical profiles over time, each month of hospital admission was associated with an estimated 5% lower odds of 30-day mortality (adjusted odds ratio [OR] = 0.95, 95% confidence interval: 0.93-0.97, In our large LHS, near real-time changes in clinical management of COVID-19 patients happened promptly as scientific publications and regulatory approvals occurred throughout the pandemic. Alongside these changes, patients with COVID-19 experienced lower adjusted 30-day mortality following hospital admission over time.
Identifiants
pubmed: 35860323
doi: 10.1002/lrh2.10304
pii: LRH210304
pmc: PMC9284933
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e10304Informations de copyright
© 2022 The Authors. Learning Health Systems published by Wiley Periodicals LLC on behalf of University of Michigan.
Déclaration de conflit d'intérêts
None of the authors received any payments or influence from a third‐party source for the work presented, and none report any potential conflicts of interest.
Références
N Engl J Med. 2021 Feb 25;384(8):693-704
pubmed: 32678530
JAMA Netw Open. 2021 Apr 1;4(4):e216556
pubmed: 33830226
Lancet. 2021 May 01;397(10285):1637-1645
pubmed: 33933206
Mayo Clin Proc Innov Qual Outcomes. 2021 Feb;5(1):171-176
pubmed: 33163894
Worldviews Evid Based Nurs. 2016 Feb;13(1):15-24
pubmed: 26873372
PLoS Med. 2015 Oct 06;12(10):e1001885
pubmed: 26440803
N Engl J Med. 2020 Apr 30;382(18):1677-1679
pubmed: 32109012
Ann Intern Med. 2012 Aug 7;157(3):207-10
pubmed: 22868839
Ann Intern Med. 2021 May;174(5):613-621
pubmed: 33460330
N Engl J Med. 2021 Apr 22;384(16):1491-1502
pubmed: 33631065
J Prim Care Community Health. 2020 Jan-Dec;11:2150132720966409
pubmed: 33063617
N Engl J Med. 2021 Jul 1;385(1):1-5
pubmed: 34192452
J R Soc Med. 2011 Dec;104(12):510-20
pubmed: 22179294
JAMA. 2020 Oct 6;324(13):1317-1329
pubmed: 32876697
Crit Care Explor. 2020 Jun 15;2(6):e0136
pubmed: 32695999
J Nurs Adm. 2012 Sep;42(9):410-7
pubmed: 22922750
Pharm Stat. 2017 May;16(3):210-217
pubmed: 28261972
Mayo Clin Proc. 2021 Apr;96(4):849-855
pubmed: 33714596
EClinicalMedicine. 2020 May 24;23:100377
pubmed: 32632412
Trials. 2021 May 25;22(1):363
pubmed: 34034784
N Engl J Med. 2018 May 31;378(22):2057-2060
pubmed: 29847763
Lancet Glob Health. 2021 May;9(5):e711-e720
pubmed: 33865476
J Clin Epidemiol. 2020 Jul;123:120-126
pubmed: 32330521
Trials. 2021 Feb 16;22(1):145
pubmed: 33593400
JAMA. 2020 Jul 28;324(4):329-330
pubmed: 32579158
BMJ Open. 2020 Dec 29;10(12):e041849
pubmed: 33376175
JAMA. 2020 Aug 4;324(5):453-454
pubmed: 32589195